Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2028-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neuromuscular ultrasound (NMUS) is emerging as a valuable non-invasive diagnostic tool. In GBS, NMUS can detect proximal nerve enlargement early, before neurophysiological changes. Persistent nerve enlargement can be observed up to 15 years, though its correlation with disability varies. Research is needed to clarify NMUS findings in GBS and CIDP over time. Early detection of nerve root enlargement via NMUS could facilitate earlier diagnosis and intervention, improving patient outcomes and understanding of these conditions\&#39; pathophysiology.

This study aims to determine if nerve alterations in acute GBS and CIDP detectable by ultrasound match electrodiagnostic findings and if this method aids early diagnosis. The investigators will perform serial nerve ultrasounds and NCS to investigate nerve morphology, predict outcomes, and differentiate between axonal and demyelinating subtypes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of High Frequency Ultrasound in Demyelinating Polyneuropathies

NCT04978623

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

COMPLETED

Neuromuscular Ultrasound in Correlation to Neurophysiological Findings

NCT04092140

Carpal Tunnel Syndrome Diabetic Neuropathies Guillain-Barre Syndrome

UNKNOWN

Multimodal Ultrasound in Peripheral Neuropathy

NCT06711133

Peripheral Neuropathy

NOT_YET_RECRUITING

Can Ultrasound Detect Diabetic Peripheral Neuropathy?

NCT01261442

Distal Symmetric Polyneuropathy (DSPN)

COMPLETED

Effect of Different Ultrasound Doses on Median Nerve Conduction Parameters

NCT05233488

Entrapment Neuropathies

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Guillain Barré Syndrome Chronic Inflammatory Demyelinating Polyradiculoneuropathy Peripheral Nerve Disorder Peripheral Nerves US Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Patients with immune mediated peripheral nerve disorders GB syndrome and CIDP

Placebo

Intervention Type DIETARY_SUPPLEMENT

Thiotacid 300 mg tab once/day

Control

Healthy control matching group

Placebo

Intervention Type DIETARY_SUPPLEMENT

Thiotacid 300 mg tab once/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Thiotacid 300 mg tab once/day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of patient group:

* GBS Patients: Diagnosed according to the criteria of the National Institute of Neurological Disorders and Stroke (NINDS) and the Brighton Collaboration (2011).
* CIDP Patients: Diagnosed according to the criteria of the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS).
2. Age: Participants aged 18 to 75 years.
3. Onset:

* GBS Patients: Recent onset of GBS within the first 2 weeks of symptom onset.
* CIDP Patients: Either relapsing or progressive course consistent with CIDP diagnosis.
4. Gender: Both male and female participants are eligible.
5. Participation: Willingness to participate in the study, including undergoing disease-related examinations and assessments.
6. Consent: Ability and willingness to provide informed consent

Exclusion Criteria

1. Patients unable or unwilling to provide informed consent.
2. Patients with metabolic disorders or malignancies.
3. Patients with other causes of peripheral neuropathy.
4. Patients with other causes of acute flaccid paralysis.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes